Beijing Increasepharm Corporation Limited (Increasepharm), started since 1999, headquartered in Zhongke Yungu Park, Changping District, Beijing. It is a segmentation leading enterprises of TCM with the R&D whole process. Increasepharm is a high-tech enterprise that focuses on independent R&D, to be a Contract Research Organization as well. Besides, it is also competitive in chemical drugs, especially chemical preparations.

As it develops, Increasepharm has many honors and qualifications granted by governments, such as National High-tech Enterprises, Post-doctoral Workstations, Beijing Enterprise Technology Center, Tianjin Laboratory of Pulmonary Drug Delivery Technology and Guangdong Engineering Technology Research Center for Aerosol Inhalation Preparations and CNAS certificate etc. At the same time, Increasepharm is recognized by China Association of TCM, World Federation of Chinese Medicine Societies and other 6 national societies. In addition, Increasepharm relies on them for academic research and participates in inheritance, innovation and development of the pharmaceutical industry.

Increasepharm has established 8 subsidiaries in Beijing, Tianjin, Zhuhai, Shanghai and Hong Kong. The company has five major business sections, including TCM, chemical medicine innovation, clinical service, pilot-scale production and international business; it has set 15 R&D platform resources with process management system covering project approval, preclinical research, clinical research, industrialization and commercialization of scientific and research findings. Among them, we have included more than 50,000 square meters of an R&D site, production base 60 acres, more than 1,000 precision instruments or equipments, more than 500 R&D researchers. More than 60% of them has a master's degree and senior titles or above，which contains 80 senior experts. It has undertaken more than 50 national innovation projects and research awards and multiple new drug R&D projects. Over the years, the achievements include 12 New Drug Certificates，29 Clinical Trial Authorizations，28 Drug Marketing Authorizations and 500 Patent Applications; More than 400 in research NDA and improved new drugs，which proves our outstanding innovation and R&D capabilities.

Increasepharm has partners and customer resources all over the world, providing professional and core competitiveness for services and products separately in the pharmaceutical industry. They jointly undertake more than 1,000 R&D and technical services, adding up to RMB1.5 billion.

Adhering to the business philosophy of "Innovation-driven, Excellence-aimed, Integrity-based, Win-win cooperation", Increasepharm will continue to be committed to new drug R&D and insist on pursuing development through innovation and service. With the strong R&D strength, the company aims to provide new medicine and technical services with high-tech and good market prospects and uses independent innovation technology to promote the innovation of Chinese medicine, serve for human health and progress the cause of Chinese medicine!